Meeting
2020 ASCO Virtual Scientific Program
Clinical activity and safety of penpulimab (Anti-PD-1) with anlotinib as first-line therapy for advanced hepatocellular carcinoma (HCC).
Authors
Shun Chang Jiao
Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
Shun Chang Jiao , Li Bai , Jiahong Dong , Chunmei Bai , Chunhong Hu , Liangfang Shen , Qun Qin , Yuxian Bai , Jia Fan , Aimin Zang , Chun Han , Yanyun Zhu , Juan Li , Pengfei Zhang , Sisi Ye , Xindan Kang , Qian Qiao , Weifeng Song , Baiyong Li , Yu Xia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT04172571
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4592)
DOI
10.1200/JCO.2020.38.15_suppl.4592
Abstract #
4592
Poster Bd #
200
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
First Author: Zhiwei Chang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II study of paclitaxel and carboplatin plus PD-1 inhibitors combined with anlotinib as first-line treatment for advanced esophageal cancer.
First Author: Mingfang Xu
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
The SAINT: Initial results of a phase I/II study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.
First Author: Sant P. Chawla
Poster
2016 ASCO Annual Meeting
Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study.
First Author: Bruno Sangro